A strong need for improving the education of physicians on glucocorticoid replacement treatment in adrenal insufficiency: An interdisciplinary and multicentre evaluation

Published: 20 April 2016
Author(s): Daniela Kampmeyer, Hendrik Lehnert, Heiner Moenig, Christian S. Haas, Birgit Harbeck
Issue: April 2016
Section: Letter to the Editor

Adrenal insufficiency (AI) is a rare disease with an estimated prevalence of less than 300 per million [1]. AI can either be the result of destruction of the adrenal glands (primary AI), or of dysfunction of the pituitary gland or the hypothalamus (secondary/tertiary AI). Glucocorticoid (GC) replacement as treatment in AI is intended not only to completely restore well-being in affected patients, but also to prevent life-threatening complications. As such, adrenal crisis occurs with an incidence of 5–10 patients per 100 patient years and is associated with a mortality of 0.5% [2].